Oral Ketorolac Dosing and Duration
For adult patients, oral ketorolac should be dosed at 20 mg once (or 10 mg for patients ≥65 years, renally impaired, or <50 kg), followed by 10 mg every 4-6 hours as needed with a maximum of 40 mg/day, and the combined duration of IV/IM plus oral therapy must not exceed 5 days total. 1
Dosing Algorithm
Initial Oral Dose (Following IV/IM Ketorolac)
- Adults age 17-64 years: 20 mg PO once
- Adults ≥65 years, renally impaired, OR weight <50 kg: 10 mg PO once
Maintenance Dosing
- All adult patients: 10 mg every 4-6 hours as needed
- Maximum daily dose: 40 mg/day (regardless of age or risk factors)
- Do NOT shorten the 4-6 hour dosing interval 1
Critical Limitation
Oral ketorolac is ONLY indicated as continuation therapy after IV or IM ketorolac—it should never be used as initial therapy. The FDA label explicitly states oral formulation should not be given as an initial dose. 1
Maximum Duration: 5 Days Total
The combined duration of parenteral (IV/IM) plus oral ketorolac cannot exceed 5 days in adults. 1 This strict limitation exists because prolonged therapy beyond 5 days significantly increases the risk of serious adverse events including gastrointestinal bleeding, renal impairment, and operative site bleeding. 2 The incidence of serious adverse events has declined substantially since these dosage guidelines were revised to limit duration. 2
Special Population Adjustments
Renal Impairment
Patients with renal disease show approximately 100% increase in drug exposure (AUC), with half-life extending from 5-6 hours to 10-19 hours depending on impairment severity. 1 The reduced 10 mg initial and maintenance dosing is mandatory for these patients. 1
Elderly Patients (≥65 years)
Despite only modest pharmacokinetic changes (half-life increases from 5.3 to 6-7 hours), elderly patients require the lower 10 mg dosing regimen due to increased vulnerability to adverse events. 1
Hepatic Impairment
Interestingly, there is no significant difference in pharmacokinetic parameters in patients with liver disease compared to healthy volunteers, 1 but caution is still warranted given the overall risk profile.
Evidence Supporting Lower Doses
Recent high-quality evidence demonstrates that lower doses of ketorolac provide equivalent analgesia with potentially improved safety profiles. A 2023 systematic review found that parenteral ketorolac at 15-20 mg is probably as effective as ≥30 mg doses (mean difference 0.05 mm on 100 mm VAS, 95% CI -4.91 to +5.01 mm; moderate certainty). 3 A 2024 meta-analysis confirmed that multiple intakes of 5,10, or 20 mg oral ketorolac over 1-10 days do not increase adverse event risk compared to placebo (RR = 1.39,95% CI 0.95-2.05, p = 0.093). 4
Common Pitfalls to Avoid
- Never use oral ketorolac as first-line therapy—it must follow parenteral administration 1
- Never exceed 5 days total duration (IV/IM + oral combined) 1
- Never co-administer with other NSAIDs or in patients with NSAID/aspirin allergy 5
- Never use prophylactically to prevent anticipated pain 5
- Never shorten the 4-6 hour dosing interval even if pain persists—use rescue analgesia instead 1
Absolute Contraindications
Ketorolac is contraindicated in patients with:
- History of or current risk of gastrointestinal bleeding
- Risk of renal failure or significant renal impairment
- Compromised hemostasis or active bleeding
- Hypersensitivity to aspirin or other NSAIDs
- Labor, delivery, and nursing 2